Sepsis is the leading cause of death in noncoronary intensive care units in the US. A pathognomonic feature of sepsis is severe tissue injury secondary to a profound release of host cell cytokines. Activation of tumor necrosis factor receptor associated factor (TRAF) proteins is crucial to septic inflammation as these proteins link cell surface signals to cytokine release. The mechanistic platform of this proposal resides on our discovery of a unique molecular model of innate immunity for cytokine release whereby a relatively new protein, Fbxo3, potently stimulates cytokine secretion from human inflammatory cells by destabilizing a sentinel TRAF inhibitor, Fbxl2 (Nature Immunology 14:470-9, 2013). Our pilot data indicate that Fbxo3 and TRAF proteins in circulation positively correlate with cytokine responses in septic subjects. We also identified a hypofunctional Fbxo3 human polymorphism. By targeting the prokaryotic-like Fbxo3 ApaG molecular signature, we developed a unique genus of small molecule inhibitors that lessen severity of cytokine-driven inflammation in murine models. Hence, in this application we will elucidate how Fbxo3 degrades Fbxl2 (Aim 1), test a novel chemical entity acting as a Fbxo3 ApaG inhibitor in septic models (Aim 2), and biologically characterize a Fbxo3->TRAF pathway and naturally occurring polymorphism in a prospective cohort study in subjects with sepsis (Aim 3). These studies will provide a new pathway of innate immunity that may identify subjects with altered immune responses during critical illness or provide a basis for therapeutic intervention targeting TRAF protein abundance.
Sepsis is a major cause of morbidity and mortality in the US and evidence suggests that patients die from overwhelming systemic inflammation. This inflammation is caused from the release of proteins, called cytokines. We have discovered a new model of inflammation in subjects with sepsis. This discovery led us to develop a new family of small molecules that lessen severity of cytokine-driven inflammation.
|Suber, Tomeka L; Nikolli, Ina; O'Brien, Michael E et al. (2018) FBXO17 promotes cell proliferation through activation of Akt in lung adenocarcinoma cells. Respir Res 19:206|
|Kitsios, Georgios D; Fitch, Adam; Manatakis, Dimitris V et al. (2018) Respiratory Microbiome Profiling for Etiologic Diagnosis of Pneumonia in Mechanically Ventilated Patients. Front Microbiol 9:1413|
|Kitsios, Georgios D; McVerry, Bryan J (2018) Host-Microbiome Interactions in the Subglottic Space. Bacteria Ante Portas! Am J Respir Crit Care Med 198:294-297|
|Shah, Faraaz Ali; Singamsetty, Srikanth; Guo, Lanping et al. (2018) Stimulation of the endogenous incretin glucose-dependent insulinotropic peptide by enteral dextrose improves glucose homeostasis and inflammation in murine endotoxemia. Transl Res 193:1-12|
|Evankovich, John; Lear, Travis; Mckelvey, Alison et al. (2017) Receptor for advanced glycation end products is targeted by FBXO10 for ubiquitination and degradation. FASEB J 31:3894-3903|
|Weathington, Nathaniel M; Kanth, Shreya M; Gong, Qiaoke et al. (2017) IL-4 Induces IL17Rb Gene Transcription in Monocytic Cells with Coordinate Autocrine IL-25 Signaling. Am J Respir Cell Mol Biol 57:346-354|
|Suber, Tomeka; Wei, Jianxin; Jacko, Anastasia M et al. (2017) SCFFBXO17 E3 ligase modulates inflammation by regulating proteasomal degradation of glycogen synthase kinase-3? in lung epithelia. J Biol Chem 292:7452-7461|
|Han, SeungHye; Jerome, Jacob A; Gregory, Alyssa D et al. (2017) Cigarette smoke destabilizes NLRP3 protein by promoting its ubiquitination. Respir Res 18:2|
|Kitsios, Georgios D; Morowitz, Michael J; Dickson, Robert P et al. (2017) Dysbiosis in the intensive care unit: Microbiome science coming to the bedside. J Crit Care 38:84-91|
|Lendermon, Elizabeth A; Coon, Tiffany A; Bednash, Joseph S et al. (2017) Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome-dependent inflammation. Respir Res 18:131|
Showing the most recent 10 out of 62 publications